{"url_path":"/sec/traw/8-k/2026-07-09/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","accession_number":"0001104659-26-082250","cik":"0001130598","ticker":"TRAW","issuer_name":"Traws Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-082250-index.html","primary_entity_key":"0001130598","primary_entity_name":"Traws Pharma, Inc."},"word_count":191,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nAs described in Item\n5.07 below, on July 8, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Traws Pharma, Inc. (the\n“Company”), the Company’s stockholders approved an amendment to the Company’s 2021 Incentive Compensation Plan\n(as so amended, the “Plan”), to increase the number of shares of common stock available for issuance by 2,000,000 and make\ncertain other administrative changes (the “Amendment”). The amendment to the Plan became effective on July 8, 2026 following\nreceipt of stockholder approval.\n\n \n\nAdditional information\nregarding the Plan is set forth in the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”)\nfiled by the Company with the Securities and Exchange Commission on May 29, 2026, which information is incorporated herein by reference.\nSuch information and the foregoing description of the Amendment do not purport to be complete and are qualified in their entirety by\nreference to the full text of the Amendment, a copy of which is attached to this Current Report Exhibit 10.1 and is incorporated herein\nby reference."}